Scarica l'app Stockscreener
2.38
1.28%
0.03
Dopo l'orario di chiusura:
2.48
0.10
+4.20%
Precedente Chiudi:
$2.35
Aprire:
$2.38
Volume 24 ore:
426.83K
Relative Volume:
0.45
Capitalizzazione di mercato:
$97.29M
Reddito:
-
Utile/perdita netta:
$-78.92M
Rapporto P/E:
-1.1553
EPS:
-2.06
Flusso di cassa netto:
$-72.87M
1 W Prestazione:
+8.18%
1M Prestazione:
+40.00%
6M Prestazione:
-42.93%
1 anno Prestazione:
-12.50%
Intervallo 1D:
$2.32
$2.53
Intervallo di 1 settimana:
$2.02
$2.53
Portata 52W:
$1.49
$6.06
Vigil Neuroscience Inc Stock (VIGL) Company Profile
Nome
Vigil Neuroscience Inc
Settore
Industria
Telefono
857-254-4445
Indirizzo
100 FORGE ROAD, WATERTOWN
Confronta VIGL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VIGL
Vigil Neuroscience Inc
|
2.38 | 97.29M | 0 | -78.92M | -72.87M | -2.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-04 | Iniziato | William Blair | Outperform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2022-09-16 | Iniziato | Wedbush | Outperform |
| 2022-08-29 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Iniziato | Jefferies | Buy |
| 2022-02-01 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-01 | Iniziato | Stifel | Buy |
Mostra tutto
Vigil Neuroscience Inc Borsa (VIGL) Ultime notizie
Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Neurodegenerative Disease Pioneer Vigil to Reveal Latest Developments at Major Biotech Conference - StockTitan
Vigil Neuroscience Reports Positive Data from Phase 1 Clinical Trial on Potential Alzheimer’s Treatment - Defense World
Vigil Neuroscience shares rise on positive Alzheimer's trial data - MSN
Guggenheim Reiterates Buy Rating for Vigil Neuroscience (NASDAQ:VIGL) - Defense World
Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial - MSN
Vigil Neuroscience's (VIGL) Buy Rating Reiterated at Guggenheim - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Vigil Neuroscience (NASDAQ:VIGL) - Defense World
HC Wainwright Reiterates Buy Rating for Vigil Neuroscience (NASDAQ:VIGL) - MarketBeat
Vigil moves into Phase II with Alzheimer's pill - The Pharma Letter
Vigil Neuroscience gains after early-stage data for Alzheimer’s drug (update) - MSN
Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial By Investing.com - Investing.com South Africa
Vigil Neuroscience: Now A 'Hold' Based On Two New Pipeline Developments - Seeking Alpha
Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3 - AOL
Vigil Neuroscience stock up on Alzheimer’s data (VIGL:NASDAQ) - Seeking Alpha
Vigil Neuroscience stock gains on Alzheimer’s data (VIGL:NASDAQ) - Seeking Alpha
Vigil Neuroscience Announces Positive Phase 1 Trial Results - TipRanks
Vigil Neuroscience shares rise on positive Alzheimer's trial data By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Vigil Neuroscience Reports Positive Data from its Phase 1 - GlobeNewswire
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for - The Bakersfield Californian
Vigil's Alzheimer's Drug Shows Promising Phase 1 Results with 50% Brain Biomarker Reduction - StockTitan
Vigil Neuroscience, Inc. Reports Positive Data from its Phase 1 Clinical Trial Evaluating Vv-3927 for the Potential Treatment of Alzheimer's Disease - Marketscreener.com
Glimpse Group Inc (NASDAQ: VRAR) Down -21.05% This Year: What To Expect Next - Stocks Register
Them too in TREM2: Street keeping AD Vigil - BioWorld Online
Q4 Earnings Forecast for VIGL Issued By William Blair - Defense World
Q4 Earnings Estimate for VIGL Issued By William Blair - MarketBeat
Geode Capital Management LLC Raises Position in Ballard Power Systems Inc. (NASDAQ:BLDP) - Defense World
Geode Capital Management LLC Grows Stake in Kewaunee Scientific Co. (NASDAQ:KEQU) - Defense World
Geode Capital Management LLC Purchases 66,712 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
CarGurus to Present at 27th Annual Needham Growth Conference - The Manila Times
Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones - GlobeNewswire
Vigil Neuroscience Lands $40M Sanofi Investment, FDA Signals Path for Accelerated Approval - StockTitan
Vigil Neuroscience stock hits 52-week low at $1.51 By Investing.com - Investing.com South Africa
Vigil Neuroscience stock hits 52-week low at $1.51 - Investing.com
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Significant Decrease in Short Interest - MarketBeat
Vigil Neuroscience director Budd Haeberlein buys $20,520 in shares By Investing.com - Investing.com South Africa
Vigil Neuroscience director Budd Haeberlein buys $20,520 in shares - Investing.com India
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Director Haeberlein Samantha L. Budd Purchases 12,000 Shares - MarketBeat
VIGL stock touches 52-week low at $1.61 amid market challenges - Investing.com India
VIGL stock touches 52-week low at $1.61 amid market challenges By Investing.com - Investing.com South Africa
Vigil neuroscience CEO Ivana Magovcevic-Liebisch acquires $8,350 in stock - Investing.com India
Vigil neuroscience CEO Ivana Magovcevic-Liebisch acquires $8,350 in stock By Investing.com - Investing.com Australia
Vigil Neuroscience stock hits 52-week low at $2.07 - Investing.com India
Vigil Neuroscience (NASDAQ:VIGL) and ProKidney (NASDAQ:PROK) Head-To-Head Contrast - Defense World
Vigil Neuroscience initiated with an Outperform at William Blair - MSN
FY2024 Earnings Estimate for VIGL Issued By William Blair - MarketBeat
FY2024 Earnings Forecast for VIGL Issued By William Blair - Defense World
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - The Eastern Progress Online
William Blair Initiates Coverage on Vigil Neuroscience (NASDAQ:VIGL) - Defense World
Vigil neuroscience CEO Ivana Magovcevic-Liebisch buys $11,700 in stock By Investing.com - Investing.com Australia
Vigil Neuroscience Inc Azioni (VIGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):